Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Mitochondrial Transplantation: An Emerging Therapeutic Option for Cardiovascular Disease.

Created on 16 Oct 2026

Authors

Suin Park, Jehee Jang, Young-Won Kim, Jae-Hong Ko, Sungguan Hong, Sung Hoon Lee, Kei Hayashida, Ki-Woon Kang

Published in

Korean circulation journal. Jul 23, 2026. Epub Jul 23, 2026.

Abstract

Cardiovascular diseases (CVD) continue to impose the greatest global burden of death, and mitochondrial injury is increasingly recognized as a key pathological driver across ischemic heart disease, cardiac arrest, and heart failure. In this context, mitochondrial transplantation (MT) has gained attention as a promising therapeutic approach that directly addresses bioenergetic deficits by delivering functional mitochondria to compromised myocardium. This review examines current evidence for MT in CVD and evaluates its translational potential. We comprehensively reviewed preclinical studies and early clinical data on MT in CVD models, focusing on isolation techniques, delivery mechanisms, cellular uptake pathways, and therapeutic outcomes. Key databases were searched for relevant studies published through November 2025. MT demonstrates significant cardioprotective effects across diverse CVD models, including reduction in infarct size, restoration of adenosine triphosphate production, and improved functional recovery. Multiple cellular uptake mechanisms have been investigated, including actin-dependent endocytosis, macropinocytosis, and tunneling nanotubes. Advanced delivery strategies incorporating surface modifications, hydrogel platforms, and targeted peptides have improved mitochondrial stability and homing efficiency. Proposed mechanisms extend beyond bioenergetic rescue to include modulation of autophagy, oxidative stress reduction, and immunometabolic regulation. However, critical challenges remain regarding uptake efficiency, biodistribution, persistence, standardization protocols, and immunological considerations. MT represents a paradigm-shifting approach to cardiovascular therapeutics with encouraging preclinical results. Rigorous clinical trials with standardized methodologies are essential to establish safety, efficacy, and optimal implementation strategies for clinical translation.

PMID:
42885731
Bibliographic data and abstract were imported from PubMed on 16 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 14
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement